KRASCENDO 1: diva v soto/adag; off inhibitor; pretreated; n338: PFS HR 0.58; 4.1m longer mPFS; OS HR 0.56; 5.7m longer OS; mDOR 11.9m ORR 58%; CNS activity not as deep; #ESMO26 @BT

Dr Riyaz Shah· @DrRiyazShah · X·2026-10-25 23:42· 1 天前评分70

正文 · 机器翻译

KRASCENDO 1：diva 对比 soto/adag；已停用抑制剂；既往经治；n338：PFS HR 0.58；mPFS 延长4.1个月；OS HR 0.56；OS 延长5.7个月；mDOR 11.9个月，ORR 58%；CNS 活性较浅；#ESMO26 @BTOGORG

38 浏览 · 1 赞 · 1 转发 · 0 回复

会议摘要

2551TIPNCT07541170 NCT07541170 NCT07541170按 NSCLC, early stage 对上

Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer

https://esmocongress.esmo.org

来源：Dr Riyaz Shah · x.com